Viewing Study NCT03207750

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:01 PM
Ignite Modification Date: 2026-02-01 @ 6:04 AM
Study NCT ID: NCT03207750
Status: COMPLETED
Last Update Posted: 2020-12-29
First Post: 2017-06-16
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Rotavirus Infection View
None Rotavirus Vaccines View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunogenicity View
None lyophilized formulation View
None United States View
None Reactogenicity View
None Safety View
None Porcine circovirus -free View
None Human rotavirus vaccine View
None liquid formulation View
None Healthy infants View